



SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

Ref: SPL/CORP-SEC/2020-21/BSE/1327

Dated: 13.02.2021

To,

Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting for the FY 2020-21 held on Saturday, 13th February 2021 with Scrip Code 524703.

A Meeting of the Board of Directors of the Company duly convened on Saturday, 13th February 2021 **at 4:30 p.m. and Concluded at 8.00 p.m.** at the Corporate Office of the Company at Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai 400071 inter alia, discussed the following business:-

- (a) It has approved Unaudited Financial Results for the Quarter ended 31st December 2020 along with Limited Review Report.
- (b) It has Re-appointed M/s Lalit Gawde & Associates, and Shri. Akhil Pai, Chartered Accountant as the Internal Auditor for the Financial year 2021-22.

You are requested to kindly take the same on record.

Yours Faithfully,

For Sandu Pharmaceuticals Limited



Company Secretary



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN:L24233GA1985PLC001587



1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 have been reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 13th February 2021. The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.
2. The Company has considered the possible impact of COVID-19 pandemic on its operations, liquidity position and recoverability of its asset balances at 31st December, 2020 based on the internal and external information upto the date of approval of these financial results. The impact of COVID-19 may be different from that estimated as at the date of approval of these financial results and management will continue to monitor any material changes arising due to the impact of this pandemic on financial and operational performance of the Company and take necessary measures to address the situation.
3. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Property Medicines". Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.
4. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at the meeting held on 13th February, 2021. there are no qualifications in the limited review report issued for the nine months & quarter ended December 2020.
5. Figures for the previous periods have been reclassified/regrouped, whenever necessary

Place: - Mumbai

Date: - 13/02/2021

For Sandu Pharmaceuticals Ltd


Umesh Sandu
Managing Director
DIN :- 01132141





Dileep & Prithvi

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE UNAUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER, 2020, PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)

To,

**The Board of Directors,
Sandu Pharmaceuticals Limited,
Plot No. 25, 26, 29 & 30,
Pilerne Industrial Estate, Marra,
Bardez, Goa-403511.**


Dear Sirs,

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Sandu Pharmaceuticals Limited** ("the Company") for the quarter and nine months ended on 31st Dec, 2020, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind As 34), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (*SRE*) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Dileep & Prithvi

Chartered Accountants

Firm Registration Number: 122290W


Himmat Mali

(Partner)

Membership Number: 183378

UDIN- 21183378AAAAAW6124



Place: Mumbai

Date: 13th February, 2021